SCHEMBL1642234

SCHEMBL1642234

O=C(NCc1ccc(Cl)c(Cl)c1)c1cn(Cc2ccc(C(F)(F)F)cc2)c(=O)cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
P2RX1 P51575 1/20 0.45
TMPRSS4 Q9NRS4 1/20 0.45
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44
CCR1 P32246 2/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CNR1 P21554 2/20 0.42
CNR2 P34972 1/20 0.42
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642162 0.90 LMNA (0.43) WDR5LMNAHPGDP2RX1TMPRSS4
SCHEMBL1641375 0.87 HSP90AA1 (0.53) LMNAHPGDHTTMAPTALDH1A1
SCHEMBL1641394 0.86 CNR1 (0.53) LMNAHPGDHTTMAPTALDH1A1
SCHEMBL1641080 0.82 LMNA (0.47) LMNAALDH1A1KDM4ECNR1CNR2
SCHEMBL1641018 0.80 CNR1 (0.49) WDR5HPGDALDH1A1CNR1CNR2
SCHEMBL1642095 0.80 EGLN3 (0.66) WDR5LMNAHPGDALDH1A1KDM4E
SCHEMBL1640586 0.79 TSHR (0.50) LMNAHPGDALDH1A1CNR1CNR2
SCHEMBL1641936 0.77 KDM4E (0.57) LMNAHTTMAPTALDH1A1KDM4E
SCHEMBL1640326 0.77 HSP90AA1 (0.58) LMNAHPGDHTTMAPTALDH1A1
SCHEMBL1642163 0.76 CNR1 (0.52) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 WDR5 1791/4885LMNA 3462/4885HPGD 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.